Hepatitis C drug patent challenged in Europe
Campaign group says Gilead’s expensive blockbuster sofosbuvir is not innovative enough to warrant a patent
Campaign group says Gilead’s expensive blockbuster sofosbuvir is not innovative enough to warrant a patent